‘Red Flags’ and ‘Red Tape’: Telehealth and pharmacy-level barriers to buprenorphine in the United States
Authors:
- 10 May 2022
- journal article
- research article
- Published by Elsevier in International Journal of Drug Policy
- Vol. 105, 103703
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- White opioids: Pharmaceutical race and the war on drugs that wasn’tBioSocieties, 2017
- Pharmacists' readiness to provide naloxone in community pharmacies in West VirginiaJournal of the American Pharmacists Association, 2017
- The War on Drugs Comes to the Pharmacy Counter: Frontline Work in the Shadow of Discrepant Institutional LogicsLaw & Social Inquiry, 2015
- Variation in Use of Buprenorphine and Methadone Treatment by Racial, Ethnic, and Income Characteristics of Residential Social Areas in New York CityThe Journal of Behavioral Health Services & Research, 2013
- Factors influencing pharmacy services in opioid substitution treatmentDrug and Alcohol Review, 2013
- Structural Vulnerability and Health: Latino Migrant Laborers in the United StatesMedical Anthropology, 2011
- Current Knowledge of Buprenorphine and Its Unique Pharmacological ProfilePain Practice, 2010
- Risk environments and drug harms: A social science for harm reduction approachInternational Journal of Drug Policy, 2009
- Qualitative research methodologies: ethnographyBMJ, 2008
- The ‘risk environment’: a framework for understanding and reducing drug-related harmInternational Journal of Drug Policy, 2002